China Pharmaceutical University

www.cpu.edu.cn/
Nanjing, China

China Pharmaceutical University is a university in Nanjing, China that specializes in the pharmaceutical science. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

Patent
Jiangsu Kanion Parmaceutical Co. and China Pharmaceutical University | Date: 2015-06-17

A new use of a compound as indicated in structural formula I in preparing medications for preventing and/or treating pulmonary fibrosis includes the compound having the structure as indicated in structural formula 1 that substantially reduces the inflammation of diseased lung tissue, lowers the concentration of fibrosis factors TGF-I in diseased lung tissue, decreases the excessive deposition of collagen in diseased lung tissue, and has substantial prevention and treatment effectiveness against fibrosis.


Patent
Jiangsu Kanion Parmaceutical Co. and China Pharmaceutical University | Date: 2017-06-07

Disclosed is a new use of a compound as indicated in structural formula I in preparing medications for preventing and/or treating pulmonary fibrosis. The compound having the structure as indicated in structural formula 1 substantially reduces the inflammation of diseased lung tissue, lowers the concentration of fibrosis factors TGF-l in diseased lung tissue, decreases the excessive deposition of collagen in diseased lung tissue, and has substantial prevention and treatment effectiveness against fibrosis.


New research in The FASEB Journal suggests that PGLP-1 can inhibit gluconeogenesis, improve glycemic control as a therapy to insulin in type 1 diabetes, and improve insulin resistance in type 2 diabetes According to research published online in The FASEB Journal, scientists have discovered a dual peptide called "PGLP-1" that promotes insulin secretion and inhibits gluconeogenesis (a metabolic process that produces glucose). A related compound called GLP-1 is currently used in diabetes treatments. This new compound shows the potential to improve glycemic control for patients with type 1 diabetes and ameliorate insulin resistance in patients with type 2 diabetes. "In the future, I hope that, in patients with type 1 diabetes mellitus, this peptide can protect islets and lower fasting blood glucose, thereby delaying the process of diabetes and maintaining blood glucose stability," said Liang Jin, Ph.D., a researcher involved in the work at the State Key Laboratory of Natural Medicines at the Juangsu Key Laboratory of Drug Screening (School of Life Science and Technology, China Pharmaceutical University, Jiangsu Sheng, China). "In patients with type 2 diabetes, it can stimulate insulin secretion and ameliorate insulin resistance, thereby reducing the amount of insulin." Scientists designed six GLP-1 analogues and screened to obtain a dual-functional candidate peptide PGLP-1 in vivo and in vitro. The insulin secretion-promoting (insulinotropic) function was verified in normal c57 mice. In STZ-induced hyperglycemic mice, researchers demonstrated that PGLP-1 not only acts as a GLP-1RA, but also produces GLP-1(9-38) to play an insulin-like role (inhibiting gluconeogenesis), in turn protecting β cells and lowering blood glucose. "This work reveals that the gluconeogenic pathway is subject to effective pharmacological control by this peptide," said Thoru Pederson, Ph.D., Editor-in-Chief of The FASEB Journal. "Despite great strides in both type 1 and type 2 diabetes over the years, each new finding like this is most welcome." Submit to The FASEB Journal by visiting http://fasebj. , and receive monthly highlights by signing up at http://www. . The FASEB Journal is published by the Federation of the American Societies for Experimental Biology (FASEB). It is among the world's most cited biology journals and has been recognized by the Special Libraries Association as one of the top 100 most influential biomedical journals of the past century. FASEB is composed of 30 societies with more than 125,000 members, making it the largest coalition of biomedical research associations in the United States. Our mission is to advance health and welfare by promoting progress and education in biological and biomedical sciences through service to our member societies and collaborative advocacy. Details: Huashan Gao, Qian Zhao, Ziwei Song, Zhaocong Yang, You Wu, Shanshan Tang, Murad Alahdal, Yanfeng Zhang, and Liang Jin. PGLP-1, a novel long-acting dual-function GLP-1 analog, ameliorates streptozotocin-induced hyperglycemia and inhibits body weight loss. FASEB J. doi:10.1096/fj.201700002R ; http://www.


RATIONALE:: Endothelial progenitor cells (EPCs) respond to SDF-1 through receptors CXCR7 and CXCR4. Whether SDF-1 receptors involves in diabetes induced EPCs dysfunction remains unknown. OBJECTIVE:: To determine the role of SDF-1 receptors in diabetic EPCs dysfunction. METHODS AND RESULTS:: CXCR7 expression, but not CXCR4 was reduced in EPCs from db/db mice, which coincided with impaired tube formation. Knockdown of CXCR7 impaired tube formation of EPCs from normal mice, while up-regulation of CXCR7 rescued angiogenic function of EPCs from db/db mice. In normal EPCs treated with oxidized low-density lipoprotein (ox-LDL) or high glucose (HG) also reduced CXCR7 expression, impaired tube formation and increased oxidative stress and apoptosis. The damaging effects of ox-LDL or HG were markedly reduced by SDF-1 pretreatment in EPCs transduced with CXCR7 lentivirus (CXCR7-EPCs) but not in EPCs transduced with control lentivirus (Null-EPCs). Most importantly, CXCR7-EPCs were superior to Null-EPCs for therapy of ischemic limbs in db/db mice. Mechanistic studies demonstrated that ox-LDL or HG inhibited Akt and GSK-3β phosphorylation, nuclear export of Fyn and nuclear localization of Nrf2, blunting Nrf2 downstream target genes HO-1, NQO-1 and catalase, and inducing an increase in EPC oxidative stress. This destructive cascade was blocked by SDF-1 treatment in CXCR7-EPCs. Furthermore, inhibition of PI3K/Akt prevented SDF-1/CXCR7-mediated Nrf2 activation and blocked angiogenic repair. Moreover, Nrf2 knockdown almost completely abolished the protective effects of SDF-1/CXCR7 on EPC function in vitro and in vivo. CONCLUSIONS:: Elevated expression of CXCR7 enhances EPC resistance to diabetes-induced oxidative damage and improves therapeutic efficacy of EPCs in treating diabetic limb ischemia. The benefits of CXCR7 are mediated predominantly by an Akt/GSK-3β/Fyn pathway via increased activity of Nrf2. © 2017 American Heart Association, Inc.


The present invention relates to the field of natural pharmaceutical chemistry, and in particular, to a resveratrol dimer (7R,8R)-trans--viniferin (I), a preparation process therefor and a purpose thereof in lowering a blood sugar level. According to the present invention, an R type of resveratrol dimer is separated from the resveratrol dimer by using high-speed countercurrent chromatography. Pharmacodynamic tests proved that the R type of resveratrol dimer has a better effect in lowering a blood sugar level than a racemate.


The present invention relates to the field of natural pharmaceutical chemistry, and in particular, to a resveratrol dimer (7R,8R)-trans--viniferin (I), a preparation method therefor and a use thereof in reducing a blood sugar level. According to the present invention, an R type of resveratrol dimer is separated from the resveratrol dimer by using high-speed countercurrent chromatography. Pharmacodynamic tests proved that the R type of resveratrol dimer has a better effect in reducing a blood sugar level than a racemate.


Patent
China Pharmaceutical University | Date: 2014-01-07

The present invention relates to the field of medicinal chemistry, and in particular relates to 4-(five-membered heterocyclic pyrimidine/pyridine substituted) amino-1H-3-pyrazolecarboxamide derivatives, the preparation method thereof, pharmaceutical compositions containing these compounds and the medicinal use thereof, especially as protein kinase inhibitors for anti-tumour use.


Patent
China Pharmaceutical University | Date: 2014-10-15

The present invention relates to the field of medicine and particularly relates to the application of fluoxetine to the treatment of depigmentation diseases. Pharmacodynamic tests have demonstrated that fluoxetine has the effects of treating depigmentation diseases especially leukotrichia and vitiligo.


Patent
China Pharmaceutical University | Date: 2015-12-16

The present invention relates to the field of medicinal chemistry, and in particular relates to 4-(five-membered heterocyclic pyrimidine/pyridine substituted) amino-1H-3-pyrazolecarboxamide derivatives, the preparation method thereof, pharmaceutical compositions containing these compounds and the medicinal use thereof, especially as protein kinase inhibitors for anti-tumour use.


Disclosed are bifunctional fusion proteins having Tumstatin active fragments and CD137L extracellular regions. The proteins exhibit activities to inhibit the proliferation of human umbilical vein endothelial cells and to costimulate the proliferation of T cells. They can be used for the treatment of various tumor-related diseases and the regulation of angiogenesis and immunological effects in humans.

Loading China Pharmaceutical University collaborators
Loading China Pharmaceutical University collaborators